Bouncing back from a PhII flop in schizophrenia, Neurocrine steers into the busy M4/M1 pathway with a $100M cash deal

John Carroll

Editor & Founder

Eight months after Neurocrine $NBIX chronicled a flop for a mid-stage schizophrenia drug, the biotech is headed right back into Phase II armed with a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bouncing back from a PhII flop in schizophrenia, Neurocrine steers into the busy M4/M1 pathway with a $100M cash deal

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Eikon Therapeutics raises $351M Series D as lead drug starts Phase 3

Merck says Keytruda could be up next for IRA price cuts

Leo Pharma says its yearslong makeover is about to pay off

Ginkgo uncertain over the future of US government funding, stock drops

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

How AI can address ongoing challenges in the life sciences industry

Bounc­ing back from a PhII flop in schiz­o­phre­nia, Neu­ro­crine steers in­to the busy M4/M1 path­way with a $100M cash deal

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Bouncing back from a PhII flop in schizophrenia, Neurocrine steers into the busy M4/M1 pathway with a $100M cash deal